JDRF Canada welcomes new Chief Scientific Officer, Dr. Sarah Linklater
We are pleased to announce Dr. Sarah Linklater has been appointed as Chief Scientific Officer (CSO). Sarah has over a decade of extensive experience as a professional scientific editor, with a focus on clinical diabetes and endocrinology, basic immunology and other areas of the life sciences. In her role as JDRF Canada’s CSO, Sarah will lead the progress of our research partnerships and support our efforts to effectively engage the type 1 diabetes (T1D) community.
“I’m really excited for the opportunity to shape T1D research in Canada, and work with a global organization whose mission is to improve the lives of people living with T1D and ultimately cure this disease,” said Sarah.
“We are thrilled to have Sarah join our passionate team of professionals. She brings a unique combination of scientific experience and communications expertise that will help us accelerate our research program”, said Dave Prowten, President and CEO of JDRF Canada.
Sarah completed her PhD in Experimental Medicine at the UBC Faculty of Medicine under the supervision of Professor Megan Levings, a JDRF funded researcher. She has published several peer-reviewed research articles, reviews and book chapters on the function of regulatory T cells in health and autoimmune disease. In her latest role, she helped to launch The Lancet Diabetes & Endocrinology, now the leading clinical diabetes journal worldwide, and became Editor-in-Chief in 2017. Sarah will start her new role on April 16, 2019.
Click here to read our press release.